Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-706 vs Standard of Care in Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Primary completion
- Sep 2030
- Countries
- 10
01
Overview
A Phase 3 trial of turmetabart adizutecan in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Started Jul 2026; status: recruiting.
02
Drugs
turmetabart adizutecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07365241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365241.